Ireland’s largest cancer research initiative launches second phase
The second phase of Precision Oncology Ireland (POI), the country’s largest cancer research programme has been launched by James Lawless, minister for Further and Higher Education, Research, Innovation and Science. Precision Oncology Ireland is focused on advancing personalised cancer research and care.
POI is a national research consortium, focused on advancing personalised cancer research and care. Operating under a strategic partnership model, it brings together Research Ireland, the national research and innovation funding agency, with five universities, six cancer research charities and seven international companies to develop new diagnostics and therapeutics.
Minister Lawless said: “Breakthroughs in cancer research are most likely when clinicians, scientists, industry leaders, patients, charities and other stakeholders come together with a shared purpose. The first phase of Precision Oncology Ireland stands as proof that strong, sustained collaboration can unlock innovation and accelerate transformative solutions.”
The first phase of the initiative (POI-1) centred on establishing these partnerships and creating a sustainable cross-sector collaboration model. The consortium is coordinated by the Systems Biology Ireland Centre at University College Dublin (UCD), a multidisciplinary research centre led by Professor Walter Kolch.
“Research is the engine behind new medicines. POI-2 is all about linking top-notch cancer research to clinical translation. This includes the development of advanced computer simulations of the disease, so that we can design the best diagnostic and treatment approaches for each individual patient,” said Kolch.
The second phase (POI-2) will build on this foundation by enhancing clinical engagement and strengthening patient and public involvement. It will also expand training opportunities and deepen connections between research and healthcare communities.
POI-2 has secured €28m in funding from Research Ireland and its industry and not-for-profit partners – double the investment received during the first phase.
Diarmuid O’Brien, CEO, Research Ireland, said: “The highly-impactful Precision Oncology Ireland strategic partnership is enabling breakthroughs in cancer biology, supporting the development of new treatments, training the next generation of researchers, nurturing biotech start-ups, and strengthening critical research infrastructure. This programme has built a unified community that is creating a lasting impact on how we approach cancer research in Ireland. Phase 2, now, represents a substantial increase in investment, scale and ambition, as we work to deliver the next generation of cancer care.”
